Skip to main content

Table 1 The blood pressures, weights, and biochemistry data

From: The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

 

WKY (n = 9)

SHR (n = 7)

EMPA (n = 7)

P value (ANOVA)

Body weight (g)

511.2 ± 26.8

452.0 ± 17.3a

420.9 ± 18.4bc

< 0.0001

Heart weight (g)

1.92 ± 0.14

2.40 ± 0.43a

2.44 ± 0.26b

0.0029

Systolic pressure (mmHg)

80.7 ± 4.3

114.7 ± 3.8a

83.0 ± 2.7c

0.002

Diastolic pressure (mmHg)

47.0 ± 5.6

87.7 ± 5.3a

45.4 ± 3.6$

0.002

 

WKY (n = 5)

SHR (n = 7)

EMPA (n = 7)

P value (ANOVA)

Fructosamine (µmol/L)

254.3 ± 66.9

155.2 ± 44.9a

144.6 ± 61.7b

0.0027

BUN (mg/dL)

12.9 ± 1.8

21.8 ± 1.6a

22.5 ± 4.8b

0.0002

Creatinine (mg/dL)

0.56 ± 0.07

0.59 ± 0.10

0.47 ± 0.07c

0.0519

AST (IU/L)

167.3 ± 52.5

190.0 ± 40.6

262.5 ± 138.6

0.1919

ALT (IU/L)

74.3 ± 68.4

174.2 ± 89.0

225.5 ± 194.3

0.1927

Uric acid (mg/dL)

1.79 ± 1.09

2.92 ± 0.82

2.39 ± 1.05

0.1731

Triglyceride (mg/dL)

79.8 ± 9.0

59.4 ± 6.7a

58.4 ± 7.3b

0.0003

Total cholesterol (mg/dL)

120.1 ± 10.0

64.6 ± 6.8a

64.6 ± 23.9b

< 0.0001

LDL-C (mg/dL)

33.6 ± 4.9

18.7 ± 4.7a

17.1 ± 7.2b

0.0003

HDL-C (mg/dL)

90.7 ± 7.2

47.5 ± 4.3a

49.2 ± 21.2b

< 0.0001

ANP (pg/mL)

82.8 ± 18.6

158.8 ± 69.1

93.8 ± 17.5

0.0659

  1. Data are presented as mean ± standard deviation
  2. With Tukey’s multiple comparison test
  3. aComparisons significant for SHR vs WKY
  4. bComparison significant for EMPA vs WKY
  5. cComparison significant for EMPA vs SHR